Dynavax Technologies Corporation (NASDAQ:DVAX), NVIDIA Corporation (NASDAQ:NVDA)

On Monday, Shares of Dynavax Technologies Corporation (NASDAQ:DVAX), subtract -64.66% and closed at $4.10 in the last trading session. The last trading range of the stock ranges between $3.20 and $4.70. The company’s Market capitalization is $162.16 million with the total Outstanding Shares of 38.53 million. During the 52-week trading session the minimum price at which share price traded, registered at $3.20 and reached to max level of $29.86. The EPS of company is strolling at -2.87. Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the United States. Its development programs focuses on vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases. The company’s lead products include HEPLISAV-B, an investigational adult hepatitis B vaccine, which is in Phase III clinical trials; and SD-101, a C Class CpG TLR9 agonist for the treatment of cancer, which is in Phase I/II multicenter clinical trial. Its product portfolio also comprises AZD1419 for the treatment of asthma, which is in Phase II clinical trial; DV1179, a TLR7/9 inhibitor that is in Phase Ib/IIa for the treatment of autoimmune and inflammatory conditions; and DV281 and CpG-Nanoparticles, which are in preclinical studies for cancer immunotherapy. It has a research partnershipand license agreement with AstraZeneca AB to conduct a Phase IIa safety and efficacy trial of AZD1419 for the treatment of asthma; and planned alliance with GlaxoSmithKline to discover, develop, and commercialize TLR inhibitors.

Shares NVIDIA Corporation (NASDAQ:NVDA), dropped -4.92% and closed at $83.64 in the last trading session. The last trading range of the stock ranges between $83.62 and $88.19. The company’s Market capitalization is $56.27 Billion with the total Outstanding Shares of 538.00 million. During the 52-week trading session the minimum price at which share price traded, registered at $24.75 and reached to max level of $88.77. The EPS of company is strolling at 1.91. NVIDIA ( NASDAQ : NVDA ) recently declared that it is teaming up with the National Cancer Institute, the U.S. Department of Energy (DOE) and several national laboratories on an program to accelerate cancer research.

The program — known as the Cancer Moonshot, declared by President Barack Obama during his 2016 State of the Union Address, and led by Vice President Joseph Biden — aims to deliver a decade of advances in cancer prevention, diagnosis and treatment in just five years. The research efforts include a focus on building an AI framework called CANDLE (Cancer Distributed Learning Environment), which will provide a common discovery platform that brings the power of AI to the fight against cancer.

CANDLE will be the first AI framework designed to change the way we understand cancer, providing data scientists around the world with a powerful tool against this disease.

Leave a Reply

Your email address will not be published. Required fields are marked *